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Background: Increasing evidence has suggested that dysregulation of certain microRNAs (miRNAs) may contribute
to human disease including carcinogenesis and tumor metastasis in human. miR-124-3p is down-regulated in various
cancers, and modulates proliferation and aggressiveness of cancer cells. However, the roles of miR-124-3p in human
bladder cancer are elusive. Thus, this study was conducted to investigate the biological functions and its molecular
mechanisms of miR-124-3p in human bladder cancer cell lines, discussing whether it has a potential to be a therapeutic
biomarker of bladder cancer.
Methods: Three human bladder cancer cell lines and samples from ten patients with bladder cancer were analyzed for
the expression of miR-124-3p by quantitative RT–PCR. Exogenetic overexpression of miR-124-3p was established by
transfecting mimics into T24, UM-UC-3 and J82 cells, after that cell proliferation and cell cycle were assessed by MTT
assay, flow cytometry and Colony-forming assay. Cell motility and invasion ability were evaluated by wound healing
assay and transwell assay. Tissue microarray, and immunohistochemistry with antibodies against ROCK1, MMP2 and
MMP9 was performed using the peroxidase and DAB methods. The target gene of miR-124-3p was determined by
luciferase assays, quantitative RT–PCR and western blot. The regulation of epithelial-to-mesenchymal transition by
miR-124-3p was analyzed by western blot.
Results: miR-124-3p is frequently down-regulated in bladder cancer both in three bladder cancer cell lines, T24,
UM-UC-3, J82 and clinical samples. Overexpression of miR-124-3p induced G1-phase arrest in T24, UM-UC-3 and J82 cell
lines and suppressed cell growth in colony-forming assay. miR-124-3p significantly repressed the capability of migration
and invasion of bladder cancer cells. In addition, ROCK1 was identified as a new target of miR-124-3p. ROCK1, MMP2,
MMP9 were up-regulated in bladder cancer tissues. Furthermore, we demonstrated miR-124-3p could inhibit bladder
cancer cell epithelial mesenchymal transfer, and regulated the expression of c-Met, MMP2, MMP9.
Conclusions: miR-124-3p can repress the migration and invasion of bladder cancer cells via regulating ROCK1. Our
data indicate that miR-124-3p could be a tumor suppressor and may have a potential to be a diagnostics or predictive
biomarker in bladder cancer.
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Bladder cancer (BCa) is listed as the 7th of the most
common cancer in men and the 17th in women world-
wide [1]. It is associated with accumulation of chromo-
somal anomalies, genetic polymorphisms and epigenetic
changes [2]. Approximately 70% of bladder tumors are
classified as nonmuscle invasive tumors, whereas the
remaining cases have invasive potential. Most patients
with nonmuscle invasive tumors are treated by trans-
urethral resection, with a 40% to 80% risk of recurrence
and a 10% to 27% chance of progressing to muscle-
invasive, regional, or metastatic disease. About 25% of
patients with newly diagnosed bladder cancer have
muscle invasive disease, the vast majority presents with
cancers of high histological grade. Furthermore, almost
50% of bladder cancer with muscle-invasive already have
asymptomatic and nonpalpable distant metastases [3].
The limitations of established bladder cancer biomarkers
requires us to identify better molecular parameters that
could be clinically useful for diagnosis and prognosis, in
particular, for the high-risk patient groups that are usually
at high risk of progression, recurrence and metastasis.
MicroRNAs (miRNAs) are small (approximately 22-
nucleotides), endogenous, noncoding RNAs, functioning
as negative regulators of gene expression through anti-
sense complimentarily to their target messenger RNAs.
miRNAs could induce post-transcriptional gene depres-
sion by the repressing of the translation or promoting
the degradation of specific mRNAs [4,5]. Increasing evi-
dence revealed that disordered expression of miRNA
contributes to the initiation and progression of human
cancer [6]. It has been shown that miRNAs participate
in human carcinogenesis as either tumor suppressors or
oncogenes. Specifically, aberrant regulation of miRNAs
in bladder cancer was suggested to contribute to bladder
tumorigenesis [7,8]. Moreover, the profile of altered
miRNAs appears distinct between noninvasive (including
carcinoma in situ [CIS]) and muscle-invasive high-grade
cancers [9]. Some of those miRNAs could be potential
biomarkers for bladder cancer in diagnosis, prognosis
predicting and treatment target. For instance, miR-143,
miR-222, and miR-452 detected in urinary specimens
were clinically useful for noninvasive bladder cancer
diagnostics [10], and miR-9, miR-182, and miR-200b was
found to be related to bladder tumor aggressiveness and
survival [11].
The miR-124-3p was detected in 46 animal species
from Caenorhabditis to Homo sapiens [12] and it is in-
evitable in neurogenesis [13]. Recent reports further
demonstrated that decreased expression of miR-124-3p
is related to carcinogenesis. The epigenetic silencing of
miR-124-3p suggests its potential tumor suppressive
function in glioma, oral squamous cell carcinomas, he-
patocellular carcinoma (HCC) and breast cancer [14-17].miR-124-3p regulates cell cycle and motility by targeting
to CDK6 and ITGB1 [15,18]. A study reported that miR-
124-3p was deregulated in bladder cancer tissues and
cell lines because of methylation, by which they believed
that it could serve as a diagnostic biomarker for BCa de-
tection. Restoration of miR-124 may be an effective anti-
cancer therapy [19]. However, the specific function of
miR-124-3p in bladder cancer progression, especially its
molecular mechanisms by which miR-124-3p exerts its
functions and modulates the malignant phenotypes of
bladder cancer cells, has not been fully understood.
In this study, we demonstrated the pathologically
down-regulation of miR-124-3p in both bladder cancer
specimens and cell lines. Ectopic overexpression of miR-
124-3p not only repressed cell motility and invasion cap-
ability, but also triggered G1-phase arrest of human
bladder cancer cells. More importantly, we illustrated
that miR-124 directly target the Rho-associated, coiled-
coil containing protein kinase 1 (ROCK1). In addition, we
provide evidence that miR-124-3p appears to play an im-
portant role in epithelial mesenchymal transfer (EMT),
and modulates the expression of genes which promote
cancer metastasis, such as MMP2, MMP9, c-Met. Thus,
our findings provide valuable clues toward understanding
the specific tumor suppressive function and the regulatory
mechanisms of miR-124-3p in human bladder cancer.
Further investigation may present miR-124-3p as an ef-
fective therapeutic biomarker in the future.
Materials and methods
Oligonucleotide transfection
miR-124-3p mimic (named as miR-124-3p), miR-124-3p
inhibitor, negative control duplex (named as NC) and
siRNA against ROCK1 (named as siROCK1), were all
synthesized by GenePharma (Shanghai, China), were ap-
plied for transfection. Oligonucleotide transfection was
performed using Lipofectamine 2000 reagents (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The sequences were listed in Table 1.
Cell lines and cell culture
The human non-malignant cell line SV-HUC1, human
bladder cancer lines T24, UM-UC-3, J82 cells and
HEK293T cells were purchased from Shanghai Institute
of Cell Biology, Chinese Academy of Sciences and were
cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum under an humidified air atmosphere
of 5% CO2 at 37°C.
Human clinical samples
Thirteen paired bladder cancer tissues and adjacent
non-tumorous bladder mucosal tissues were obtained
from patients undergoing radical cystectomy at the First
Affiliated Hospital of Zhejiang University, China, from
Table 1 Oligonucleotide sequences
Namea Sequence (5′ to 3′)b

















aF, forward primer; R, reverse primer.
bTarget sites are in italic type; Mutated target sites are underlined.
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2013. All the patients signed informed consent and the
study was approved by the Ethical Committee of First
Affiliated Hospital of School of Medicine of Zhejiang
University. Tissue samples were trimmed and snap frozen
in liquid nitrogen until use. Tissue samples were immedi-
ately frozen in liquid nitrogen until RNA extraction.
RNA isolation and quantitative real-time PCR
Total RNA from tissue samples and cultured cells was
isolated using TRIzol reagent (Takara, Dalian, China).
Before performing Quantitative RT-PCR assays (qPCR),
RNA was reverse transcribed into miRNA cDNA and
total cDNA using One Step PrimeScript miRNA cDNA
Synthesis Kit (Takara, Dalian, China) and PrimeScript
RT reagent Kit (Takara, Dalian, China), respectively. The
mRNA and miRNA expression levels were detected by
qPCR with Applied Biosystems 7500 Fast Real-Time
PCR System real-time PCR System (Applied Biosystems,
Carlsbad, USA) with SYBR Premix Ex Taq (Takara,
Dalian, China) according to the manufacturer’s instruc-
tions and were normalized versus GAPDH mRNA and
small nuclear RNA U6, respectively. The Ct value of miR-
124-3p and ROCK1 was quantified with the 2-ΔΔCt
method.
Dual-luciferase reporter assay
Bioinformatic analysis through the online software pro-
grams TargetScan (http://www.targetscan.org/) found that
ROCK1, a potential metastasis promoter, is probably a dir-
ect target of miR-124-3p. Two oligonucleotide pairs thatcontained the desired miRNA target region and mutant
miRNA target region were designed and ordered from
Sangon, Shanghai, China. Two oligonucleotide pairs were
annealed at 90°C for 3 minutes, then transfer to 37°C for
15 minutes. The couple of annealed oligonucleotides were
then ligated into pmirGLO, Dual-Luciferase miRNA
Target Expression Vector (Promega, USA), between the
SacI and SalI sites. Both insertions were sequenced to pre-
vent any mutant. HEK293T cells were plated in 24-well
plates and co-transfected with 50 nM miR-124-3p or
NC RNA and with 100 ng of the pmirGLO. The relative
Luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega, USA) 48 h
after co-transfection.
Cell cycle analysis by flow cytometry
Cells were harvested 48 h after transfection, washed with
PBS and fixed in 75% ethanol at −20°C. After overnight
fixation, cells were washed with PBS and stained with
DNA Prep Stain (Beckman Coulter, Fullerton, CA) for
30 min. Cell cycle analysis was performed by BD LSRII
Flow Cytometry System with FACSD via software (BD
Bioscience, Franklin Lakes, USA). Data was analyzed
with ModFit LT software package.
MTT assay
Approximately 3 × 103 T24, UM-UC-3 or J82 cells were
plated in each well of a 96-well plate. After an overnight
incubation, the cells were transfected with the NC, miR-
124-3p or siROCK1 for 24–96 h. The RNA concentration
ranged from 25 to 75 nM. At various times following
treatment, the medium was removed and MTT (20 μl of
5 mg/mL, Sigma–Aldrich, St. Louis, USA) was added to
each well. The 96-well plates were incubated at 37°C for
4 h. The plates were centrifuged, and the formazan precip-
itates were dissolved in 150 μl of dimethyl sulfoxide. The
absorbance of the solution was measured at 490 nm using
a MRX II absorbance reader (DYNEX Technologies,
Chantilly, Virginia, USA).
Colony-forming assay
The cells were harvested 24 h after RNA treatment
(50 nM of NC or 50 nM of miR-124-3p). Then the
cells were resuspended in RPMI 1640 medium supple-
mented with 10% FBS and plated at a density of 500
cells/well in 6-well plate. The cultures were main-
tained under standard culture conditions for 14 days.
The estimation of colonies was performed after the
colonies were fixed with absolute methanol for 15 min
and stained with crystal violet for 20 min.
Migration and invasion assays
Cell migration and invasion were assayed using a transwell
chamber (Millipore, USA) with and without Matrigel (BD,
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chamber was placed into a 24-well plate and was coated
with 30 μl Matrigel and was incubated for forty minutes at
37°C. In both transwell assay, cells, 48 hours after trans-
fected, were trypsinized and seeded in chambers at the
density of 8 × 104 cells per well and cultured in medium
with RPMI 1640 medium with 2% serum, while 600 μl of
10% FBS–1640 was added to the lower chamber. Twenty-
four hours later, migrated cells were fixed with 100%
methanol for 30 min. Non-migrated Cells were removed
by cotton swabs. Then cells on bottom surface of the
membrane were stained by crystal violet for 20 min. Cell
images were obtained under a phase-contrast microscope
(Olympus, Tokyo, Japan).
Wound healing assays
Cells were grown to basically 100% confluence in 6-well
plates after RNAs transfection. The cell monolayers were
wounded by scraping them with a micropipette tip. The
spread of wound closure was observed after 24 h. Photo-
graphs were taken under a phase-contrast microscope
(Olympus, Japan) immediately following or 24 h after
wounding. These experiments were repeated three times.
Western blotting analysis
Cells were harvested at 48 h following various treat-
ments as described above, lysed and quantified by a
BCA kit (Thermo, USA). Proteins were separated by
10% SDS–PAGE and transferred to polyvinylidene
difluoride (PVDF) membranes. The membranes were
then blocked with 5% non-fat milk and incubated over-
night with antibodies against ROCK1, c-Met, MMP2,
MMP9, fibronectin, vimentin, N-cadherin and β-catenin
(Epitomics, Burlingame, USA), GAPDH (Sangon Bio-
tech, Shanghai, China) at dilutions specified by the man-
ufacturer’s protocol. After washed in TBS for three
times, the membranes were incubated for 1 h with
horseradish peroxidase-conjugated goat anti-rabbit sec-
ondary antibody at the 1:5000 dilution. After another
three times of washing in TBS, the bound secondary
antibody was detected using an enhanced chemilum-
inescence (ECL) system (Pierce, Biotechnology Inc.,
Rockford, USA).
Immunohistochemical (IHC) staining
Tissues microarray, which contains small representative
tissue samples from 31 of different cases and their paired
non-tumor tissues (NT), was deparaffinized, rehydrated,
and microwave-heated in sodium citrate buffer (10 mM,
pH 6.0) for antigen retrieval. Bovine Serum Albumin
was used for blocking. The slides were incubated with
ROCK1 or MMP9 antibody (Epitomics, Burlingame,
USA) or MMP2 (Santa Cruz), respectively, overnight
at 4°C at the optimal dilution, and incubated with aHRP-conjugated secondary antibody at room tem-
perature for 1 h. DAB was applied for color develop-
ment, and dark brown was considered positive staining.
The strength of positivity was semi-quantified by com-
prehensively considering staining intensity and the pro-
portion of positive cells.
Statistical analysis
The data were expressed as mean ± SD of three inde-
pendent experiments. Student’s t-test was used to com-
pare test groups with negative control ones, while
Two-way ANOVA was used to contrast the differences
among three or more experimental groups. Statistical
analysis was performed using GraphPad Prism version
5 for Windows and P < 0.05 was considered to be sta-
tistically significant.
Result
miR-124-3p is frequently down-regulated in bladder
cancer both in BCa clinical samples and cell lines
To investigate the role of miR-124-3p in human bladder
cancer, we first compared the expression levels between
three bladder cancer cell lines (T24, UM-UC-3, J82) and
non-malignant cell line SV-HUC1 by real-time RT-PCR.
The result showed that the expression levels of miR-124-3p
in all three cell lines were significantly reduced at different
degrees compared with SV-HUC1 (Figure 1A).
We further compared the expression levels of miR-
124-3p between bladder carcinomas tissue samples and
paired adjacent normal mucosal tissues from 13 cases
of bladder cancer patients. We found that miR-124-3p
expression levels were decreased in cancerous tissues
compared to their corresponding non-cancerous con-
trols (P < 0.001), with 11 out of 13 exhibiting over 50%
reduction (Figure 1B). It was consistent with data from
a previous study [19]. From these results, we speculated
that miR-124-3p may play some important roles in hu-
man bladder cancer.
miR-124-3p induces G1-phase arrest and inhibits
clonogenicity in bladder cancer cell lines
First, we performed MTT Assay to investigate whether
miR-124-3p has a biological function in proliferation of
cancer cells. No significant difference was observed be-
tween NC group and miR-124-3p treated group in MTT
assay (Data not shown). This experiment was repeated
three times. We performed flow cytometry to confirm
that exogenetic overexpression of miR-124-3p do not
suppresses bladder cell-line growth. To our surprise, a
significant accumulation of cells in the G1 phase was
observed in three cell lines after miR-124-3p treatment
(p < 0.05). This increase in G0/G1 cell population was
accompanied with a concomitant decrease of cell num-
ber in S phase and G2–M phase in three bladder cancer
Figure 1 Expression patterns of miR-124-3p in urinary bladder cancer tissues and BCa cell lines. (A) qPCR detection of miR-124-3p in T24,
UM-UC-3 and J82 cell lines versus SV-HUC-1. It was normalized with U6 snRNA in quantitative real-time RT-PCR analysis. (B) The miR-124-3p levels
were determined in 10 surgical specimens of human bladder cancer tissues and were normalized to that in the adjacent normal bladder tissues,
which is defined as 1. *P <0.05, **P < 0.01, ****P < 0.0001.
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124-3p affects cell growth, colony-forming assay was
used to evaluate the effects of miR-124-3p on cell pro-
liferation. Notably, three cell lines showed a dramatic
inhibition of clonogenicity in the miR-124-3p-treated
group (p < 0.05; Figure 2B, C). The above results sug-
gest that miR-124-3p regulates proliferation in bladder
cancer cells.
Cell migration and invasion is inhibited by miR-124-3p in
human bladder cancer
Considering T24, UM-UC-3 and J82 cells are highly
metastatic cell, we wonder whether decreased miR-124-
3p has any effect on migration and invasion capacity.
T24, UM-UC-3 and J82 cells were therefore transfected
with miR-124-3p mimics and incubated 48 h before the
wound healing assay was taken. Forced expression of
miR-124-3p in all three cells led to retarded wound clos-
ing compared to NC groups (Figure 3). Migration cham-
ber assay was used to verify the biological function of
miR-124-3p in bladder cancer cell migration. After 24 h,
the migrating cells were fixed, stained and observed
microscopically. As the representative micrographs
clearly demonstrate, miR-124-3p overexpression led to
potent inhibition of cell migration (Figure 4A).
Likewise, invasion capability of bladder cancer cells
transfected with NC or miR-124-3p was evaluated by
Matrigel invasion chamber assay. As our expected,
transfected miR-124-3p mimics in T24, UM-UC-3 and
J82 can notably repress their invasion ability compared
with NC groups (Figure 4A).
miR-124-3p directly targets ROCK1 3′-UTR
It is generally understood that miRNAs execute post-
transcriptional regulation by binding to the 3′-UTR of
their downstream genes. To find the target which is in-
volved in the regulation of cell motility and invasioncapability triggered by miR-124, we used bioinformatics
prediction software Targetscan (http://www.targetscan.
org/). Among these thousands of candidates, we focused
on ROCK1. It has been demonstrated that the Rho/
ROCK pathway participates in regulating cytoskeletal
signalling and is crucial for cell motility [20,21]. Firstly,
to investigate whether ROCK1 is upregulated in bladder
cancer, we detected its expression level in bladder cancer
tissues. In our current study, we revealed that ROCK1
was commonly over-expressed in bladder cancer tissues
by immunohistochemical staining, comparing with the
paired non-tumor tissues (NT) (Figure 5A, B). In order
to discover whether miR-124 regulates cell motility and
invasion capability via ROCK1 3′-UTR, we performed
luciferase reporter assay.
Annealed oligos containing the wild type (WT) of 3′-UTR
of ROCK1 or mutated (mut) target site was cloned into
pmirGLO Dual-Luciferase Vector (Figure 6A). HEK 293 T
cells were transiently transfected with these constructs and
miR-124-3pmimics or NC. miR-124-3pmimics significantly
suppressed the luciferase activity of reporter genes which
contains wild type of 3′-UTR of ROCK1 (Figure 6B). In
contrast, the inhibition was fully rescued when all target
sites were mutated (Figure 6B).
To further prove if miR-124-3p represses ROCK1 ex-
pression in the human bladder cancer intracellular envir-
onment, we analysed the changes of ROCK1 expression in
T24, UM-UC-3 and J82 after miR-124-3p overexpression.
By real-time RT-PCR, we found that the mRNA levels of
ROCK1 were notably reduced in miR-124-3p treated
groups, compared with that in NC groups (Figure 6D).
Meanwhile, western blot assays were taken to evaluate the
protein level of ROCK1. The results showed that ROCK1
was also dramatically decreased in protein level after ec-
topic overexpression of miR-124-3p (Figure 6C).
Collectively, these data supported our speculation that
ROCK1 is a direct target of miR-124-3p.
Figure 2 miR-124-3p induces G1-phase arrest and inhibits clonogenicity in bladder cancer cell lines. (A) The T24, UM-UC-3 and J82 cells,
transfected with NC RNA or miR-124-3p, were subjected to flow cytometry for cell cycle analysis. Three independent experiments were performed
in each group. (B) Decreased clonogenicity in bladder cancer cells treated with miR-124-3p (Representative wells were presented). (C) The colony
count was significantly lower for miR-124-3p treated group compared with NC treated group (P < 0.05).
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BCa cell migration and invasion
To explore if ROCK1 has similar function as miR-124-3p
in bladder cancer cells, RNA approach was used. The
silencing of ROCK1 was confirmed by real time RT-PCR
and western blot (Figure 6C, D). With the efficient knock-
down of ROCK1, we performed MTT assay, flow cytome-
try and colony-forming assay in T24, UM-UC-3 and J82
cell lines. There was no significant difference in both
experiments between siROCK1 groups and NC groups.
Then wound healing assays and transwell assays were
taken to observe the function of ROCK1 in bladder can-
cer cell migration and invasion. T24, UM-UC-3, J82 cells
were treated with 50 nM siROCK1, and the siROCK1
groups presented retarded wound closing and less
stained cells in wound healing assays and transwell as-
says, respectively, compared with NC groups (Figure 3
and Figure 4B). The results demonstrated that the silen-
cing of ROCK1 caused significant suppression of themigratory and invasive capability in much the same pat-
tern as miR-124-3p overexpression.
Next, to investigate if miR-124-3p exerts its function
via ROCK1 on migration and invasion of human bladder
cancer cells, we ectopically expressed ROCK1 together
with miR-124-3p in T24 cells. We inserted the human
ROCK1 coding sequence into the pTarget vector without
3′- UTR. Western blot was used to demonstrate that
ROCK1 expression was restored after transfection of
cells with this pT-ROCK1 construct (Figure 7B). 48 hours
after transfected, T24 cells were collected to perform
transwell assays. More cells in pT-ROCK1 +miR-124-3p
group than NULL +miR-124-3p group showed that
overexpression of ROCK1 abrogated the reduction of
migration and invasion ability caused by ectopic expres-
sion of miR-124-3p in T24 cells (Figure 7A). Altogether,
the above results suggest that miR-124-3p reuglates mi-
gration and invasion capability of human bladder cancer
cells via ROCK1.
Figure 3 Forced expression of miR-124-3p suppresses cell motility in wound healing assay. T24, UM-UC-3 and J82 cells were transfected
with NC, miR-124-3p mimics or siROCK1 and were performed wound healing assays with a 24-h recovery period; Scale bars = 500 μm.
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Next, we tried to find the mechanism by which miR-
124-3p suppresses cell motility and invasion ability.
Since EMT is well known to be involved in invasion and
metastasis of cancer cells, we asked whether miR-124-3p
can reverse the EMT progression. We evaluated the epi-
thelial and mesenchymal markers by western blot in
Negative control group and miR-124-overexpressingT24 cells. After miR-124 was exogenous overexpressed
in T24 cells, the expression levels of epithelial marker β-
catenin increased (Figure 7C) while the levels of three
mesenchymal markers (ie, fibronectin, N-cadherin and
vimentin) decreased, (Figure 7C). We also tried to evalu-
ate the expression level of E-cadherin, another epithelial
marker. However, E-cadherin could not be detected by
western blot in T24 cells. Other molecule promoting
cancer cells migration and invasion like c-Met, MMP2,
Figure 4 Forced expression of miR-124-3p and silenced expression of ROCK1 suppresses cell migration and invasion in transwell assay.
(A) T24, UM-UC-3 and J82 cells were transfected with NC or miR-124-3p mimics. Cell migration and invasion were assessed after 24 hours incubation
by transwell assay. (B) T24, UM-UC-3 and J82 cells were transfected with NC or siROCK1. Cell migration and invasion were evaluated after 24 hours
incubation by transwell assay; Scale bars = 100 μm.
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three mesenchymal markers, they were down-regulated
by miR-124-3p overexpression (Figure 7C).
As a possible novel target of miR-124-3p, the function
of ROCK1 in the epithelial mesenchymal transition was
further assessed via RNAi approach. As we expected, de-
creased ROCK1 could up-regulate epithelial marker, β-
catenin, and down-regulate three mesenchymal markers
(Figure 7C). siROCK1 could simulate the effect of miR-
124-3p over-expression and could reduce the expression
of c-Met, MMP2, MMP9 as well (Figure 7C). The results
indicated that overexpression of miR-124-3p represses
the EMT phenotype of bladder cancer cells.
Furthermore, as we revealed that miR-124-3p could
regulate the expression of c-Met, MMP2 and MMP9, we
were interested in its underlying molecular mechanism.
Previous studies showed that activation of RhoA/ROCK
regulates NF-κB signaling pathway and RhoA/ROCK act
upstream of p38 MAPK [22,23]. We performed western
blot to explore whether miR-124-3p could affect these
pathways. We found that both of miR-124-3p and siR-
OCK1 could decrease the expression level of Phospho-
p38 MAPK (p-p38) (Figure 7D). No significant change
of NF-κB and Phospho-NF-κB was observed (data notshow). In addition, we performed Immunohistochemical
staining to assess the expression of MMP2 and MMP9
in human bladder cancer tissues, comparing with the
paired non-tumor tissues. We confirmed that MMP2
and MMP9 were frequently up-regulated in bladder can-
cer tissues (Figure 7A, B). As we have revealed the
down-regulation of ROCK1, MMP2 and MMP9 in blad-
der cancer tissues by IHC, we wanted to know whether
knocking down miR-124-3p could result in the up-
regulation of ROCK1, MMP2 and MMP9. Therefore,
western blot was performed to investigate the expression
of these genes after knocking down miR-124-3p by syn-
thetic oligonucleotides. We found that ROCK1, MMP2
and MMP9 were up-regulated compared with the NC
groups (Additional file 1: Figure S1). It may suggest that
down-regulated miR-124-3p is one of factors which lead
to the upregulation of these genes.
Discussion
Previous studies showed that miR-124-3p is commonly
down-regulated in several human cancers and transfec-
tion of it represses cell proliferation and motility of
cancer cell lines [14-17]. Tumor-specific silencing of
miR-124-3p was a relatively frequent molecular event in
Figure 5 IHC analysis of ROCK1, MMP2 and MMP9 expression pattern in bladder cancer tissues. (A) Representative images of IHC staining for
ROCK1, MMP2 and MMP9 in human bladder cancer tissues and NT tissues were captured at 400× magnification. Scale bars = 100 μm. (B) Positive
strength of ROCK1, MMP2 and MMP9 were significantly higher in bladder cancer tissues compared with paired non-tumor tissues; P < 0.05.
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inhibitory effect, resulting in cell cycle arrest at the G1–S
checkpoint and apoptosis in cells [16]. The loss of miR-
124-3p endows breast cancer cells higher capability in mi-
gration and invasion [17]. An earlier study showed that
MicroRNA-124-3p is frequently methylated in all histo-
logical types of colorectal cancer and polyps [24]. Another
study reported that miR-124-3p was frequently methylated
in bladder cancer tissues, and the tumor tissues exhibited
significantly higher methylation levels than their non-
tumorous counterparts [19]. Thus, methylation may be an
important mechanism which contributes to the down-
regulation of miR-124-3p in bladder cancer tissues. How-
ever, the specific function of miR-124-3p in bladder cancer
progression has not been fully understood.
In this study, we reported that the expression level of
miR-124-3p was significantly lower in human bladder
cancer cell lines and tissues, which is consistent with
earlier study [19]. With the expansion of our bladdercancer tissues bank, further study at different levels
would be designed to evaluate the clinical meaning of
miR-124-3p in bladder cancer diagnosis, prognosis and
treatment. In functional studies, the results of flow
cytometry and colony-forming assay illustrated that
transfection of miR-124-3p dramatically repress prolifer-
ation in bladder cancer cell lines, while no significant
difference was observed between NC group and miR-
124-3p-treated group in MTT assay. Therefore we think
negative results occurred in viability study by MTT assay
may be due to relatively short experiment time in com-
parison with clonogenicity assay. As described in mate-
rials and methods section, we assessed cell viability
24–96 h after transfection by MTT assay, while 14 days
in clonogenicity assay. We tried to seed less amount of
cells (approximately 500 cells/well) in each well. Neverthe-
less, basically 100% confluence in 96-well plates was
reached within 5 days after RNAs transfection due to high
speed proliferation of bladder cancer cells. If we further
Figure 6 miR-124-3p directly targets ROCK1. (A) Oligonucleotides containing the predicted miR-124-3p binding sites in the 3′UTR of ROCK1
mRNA was synthetized, while mutations on the “seed” sequences are designed as below. Alignment between the predicted miR-34a target sites
and miR-124-3p is marked with black color. (B) HEK293T cells were co-transfected with 50 nM of either miR-124-3p mimics or NC and 100 ng
pmirGLO Dual-Luciferase miRNA Target Expression Vector with Wt or Mut 3′-UTR of ROCK1. The relative luciferase activity was measured 48 h after
transfection. *P < 0.05. (C) The down-expression of ROCK1 was confirmed by western blotting, after miR-124-3p or siROCK1 transfected, GAPDH
was used as control. (D) Quantitative real-time PCR analysis indicated that the relative mRNA level of ROCK1 was significantly decreased after
miR-124-3p or RNAi treatment. GAPDH was used as control. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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to assess clonogenicity of BCa cells. Therefore, despite
the discordance of results of MTT assay with results of
flow cytometry and clonogenicity assay, we suppose
miR-124-3p may inhibit cell proliferation in bladder
cancer cells. Reintroduction of miR-124-3p dramatically
repressed the capability of migration and invasion in
three human bladder cancer cell lines. These findings
suggest that miR-124-3p plays a critical role in the inva-
sive and metastatic potential of BCa and may be poten-
tial diagnostic and predictive biomarkers.
Subsequently, we demonstrated ROCK1 as direct
target of miR-124-3p in human bladder cancer. Our
findings show that miR-124-3p dramatically decreased
their expression of ROCK1 in both mRNA level and
protein level by bounding the complementary sites of its
3′-UTR. The co-transfection of pT-ROCK1 and miR-124-3p rescued the miR-124-3p induced repression in
cell motility. ROCK1 is correlated with tumor migration
and invasion and Rho/ROCK pathway participates in regu-
lating cytoskeletal signalling [20,21,25,26]. Up-regulation of
ROCK1 has been reported in bladder cancer and it has
been verified to be associated with the progression of
BCa [27]. This is consistent with our results that exoge-
netic overexpression of miR-124-3p suppress the migra-
tion and invasion of human bladder cancer cells. In
addition, cell cycle, MTT assay and colony-forming
assay presented no significant difference via RNAi ap-
proach of ROCK1, suggesting that there may be other
target genes to regulate the proliferation of BCa cells in
miR-124-3p downstream network. These observations
provide the evidence that miR-124-3p exerts its func-
tion in cell motility and invasion via regulating the ex-
pression level of ROCK1.
Figure 7 Forced expression of ROCK1 rescues miR-124-3p-associated decrease in cell migration and invasion. miR-124-3p inhibits T24
EMT. (A) T24 cells were transfected as in (B) and then used in a transwell migration assay (top) or an invasion assay (bottom). Scale bars =
100 μm (B) Either miR-124-3p mimics or NC oligos were co-transfected with the pT-ROCK1 or the empty pTarget vector, pT-NULL, into T24 cells.
Western blot was then performed to detect the expression of ROCK1. GAPDH was used as control. (C) Expression of epithelial markers and
mesenchymal markers were compared by western blot between NC and miR-124-3p or siROCK1 groups. GAPDH was used as a loading control.
(D) Expression of p-p38MAPK and p38MAPK were determined by Western blot analysis.
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are two of the most important hallmarks of malignant
tumors. EMT is thought to be a key step in the progres-
sion of tumors toward invasion and metastasis. In the
progress of EMT, epithelial cells gradually lose their epi-
thelial adherence, tight junction, polarity, cell-cell con-
tact and undergo remodeling of cytoskeleton, all of
which promotes cell motility and invasion [28]. Rho/ROCK signaling has been reported to play a key role in the
mediation of EMT [29]. In our study, we found that the
mimics of miR-124 reverses EMT of T24 cell line, as
shown by decreased expression of the mesenchymal
markers like fibronectin, N-cadherin and vimentin while
enhanced expression of the epithelial markers β-catenin.
We tried to evaluate the expression of E-cadherin, another
marker of epithelial cells. However it could not be detected
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moter may prevent its expression [30]. Here, we confirmed
that miR-124-3p reversed BCa cell EMT in vitro.
Next, we observed that the expression of c-Met,
MMP2 and MMP9 were suppressed after reintroduction
of miR-124-3p. c-Met, oncogene, is a well-characterized
cell surface receptor tyrosine kinase and up-regulated in
tumors, including human bladder cancer [31]. MMP2
and MMP9, downstream of c-Met, are two extracellular
matrix-degrading enzymes [32,33]. They endow cancer
cells high invasive and metastatic ability [34]. Silencing
of ROCK1 by siRNA could simulate the effect of miR-
124-3p over-expression, reversing EMT of T24 and
repressing c-Met, MMP2, MMP9. Furthermore, our data
suggested that miR-124-3p decreased p38 MAPK phos-
phorylation. In previous studies, p38 MAPK activation
was demonstrated to regulate MMP2, MMP9 the activity
of c-Met and can promote invasion of bladder cancer
[35-37]. Therefore, miR-124-3p may regulate the expres-
sion of c-Met, MMP2, MMP9 through p38 pathway.
These results indicated that the loss of miR-124-3p
gains the expression of ROCK1. Upregulated ROCK1
promotes BCa cells EMT which leads to migration and
invasion through Rho/ROCK pathway. Although ROCK2
was reported as a target gene of miR-124 in HCC cells
[38], we could not observe any expression difference of
ROCK2 after miR-124-3p treatment by western blot in
BCa cells (data not show). Thus, we considered that
ROCK1 is more important in miR-124-3p-Rho/ROCK
pathway in bladder cancer. It has been shown that Slug
is another target gene of miR-124-3p, which participates
in epithelial mesenchymal transition [17]. Therefore, the
loss of miR-124-3p may also result in accumulation of
Slug which promots EMT. On the other hand, ROCK1-
induced high level of c-Met, MMP2 and MMP9, which
enhances migration and invasion of bladder cancer cells.
Furthermore, our preliminary data suggested SP1 maybe
a new potential target gene of miR-124-3p. Bioinformat-
ics prediction software Targetscan predicts that SP1 may
have three binding sites of miR-124-3p. We found SP1
was down-regulated in BCa cells after miR-124-3p treat-
ment by western blot (data not show). SP1 is a widely
described gene involving in tumorigenesis, cancer metas-
tasis and proliferation [39-42]. SP1 has a key role in ini-
tiation and propagation of EMT [43], and it could
regulate the expression of Slug, c-Met, MMPs [44-46].
The results of previous studies of SP1 were consistent
with our results after miR-124-3p transfection. It is ne-
cessary to take further experiments to illustrate miR-124-
3p related downstream network in regulation of migration
and invasion of BCa cells (Figure 7). As the important role
of miR-124-3p in bladder cancer progression, we think
further experiments in animal tumor models and clinical
samples are necessary to determine the potential value ofmiR-124-3p in bladder cancer patients treatment in this
era of translational medicine.
In conclusion, we confirmed that miR-124-3p works
as a metastatic suppressor in BCa cells. The dysregula-
tion of miR-124-3p gains the expression of ROCK1,
which promotes the epithelial mesenchymal transfer and
increases c-Met, MMP2, MMP2. These mechanisms
endow the bladder cancer cells a higher capability in mi-
gration and invasion promoting tumor metastasis. We
rationally speculate that miR-124-3p has the potential to
be a useful clinical noninvasive diagnostics or predictive
marker in human bladder cancer.
Additional file
Additional file 1: Figure S1. Western blot of ROCK1, MMP2 and MMP9
after miR-124-3p inhibitor treatment. GAPDH was used as loading control.
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